Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.

NCT Number	NCT04045665
Lead Sponsor	Icahn School of Medicine at Mount Sinai Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center
Conditions	Atrial Fibrillation, Stroke, Bleeding
Enrollment	3,200 participants
Start Date	2019-12-13
Primary Completion	2026-08-31 (estimated)
Study Completion	2026-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-26